Apatinib Plus SHR1210 in Advanced Mucosal Melanoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-06-04

Study Completion Date

2022-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There is still no effective treatment for advanced mucosal melanoma at present. The efficacy of single-agent PD-1 inhibitors is less than 20%. It is urgent to explore regimens to improve the efficacy of PD-1 inhibitors in patients with advanced mucosal melanoma. This study is performed to explore the safety and efficacy of apatinib plus SHR-1210 in patients with advanced mucosa melanoma whose diseases progress after chemotherapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC

NCT04133337

Lung Diseases Neoplasms Respiratory Tract Diseases +2 more

UNKNOWN PHASE1/PHASE2

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

NCT03083041

Carcinoma, Non-Small-Cell Lung

COMPLETED PHASE2

A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

NCT06430437

Non-Small Cell Lung Cancer With HER2- Mutations

RECRUITING PHASE3

An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer

NCT03129256

Non-small Cell Lung Cancer

COMPLETED PHASE2

Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma

NCT03359018

Progression-free Survival Overall Survival Clinical Benefit Rate +1 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Apatinib is an oral small molecule anti-angiogenesis inhibitors. It inhibits VEGFR-2 tyrosine kinase activity, thereby blocking VEGF-induced signaling and exerting a strong inhibitory effect on tumor angiogenesis.Apatinib has shown anti-melanoma activity in retrospective study. However, the efficacy is still very low. SHR-1210 is an anti-PD-1 antibody produced by Hengrui Pharmaceutical Co., Ltd. Apatinib plus SHR-1210 has shown synergy in several malignancies. This study is conducted to explore the efficacy and safety in advanced mucosa melanoma

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mucosal Melanoma Advanced Cancer Apatinib SHR-1210

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

treatment group

apatinib 250mg orally once a day until disease progression of occurrence of intolerable adverse events.

SHR-1210 200mg every two weeks until disease progression of occurrence of intolerable adverse events.

(the first dose of SHR-1210 is set on the 3-5 days after apatinib

Group Type EXPERIMENTAL

apatinib plus SHR-1210

Intervention Type DRUG

apatinib 250mg qd, 3-5 days later SHR-1210 200mg q3w

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

apatinib plus SHR-1210

apatinib 250mg qd, 3-5 days later SHR-1210 200mg q3w

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* mucosal melanoma by pathology
* expected lifespan ≥ 3 months
* ECOG 0-2
* failure after one kind of chemotherapeutic regimen
* at least one measurable lesion by RECIST 1.1
* enough organ function
* blood pressure is normal; for patients with hypertension the blood pressure should be controlled in normal by antihypertensive drugs
* no other serious diseases conflicting with this regimen
* no history of other malignancies
* pregnancy test within 7 days must be negative for women of childbearing period, and appropriate measures should be taken for contraception for women in childbearing period during the study and six months after this study
* informed consent from the patient

Exclusion Criteria

* Suffering from serious infectious diseases within 4 weeks before enrollment
* requiring intermittent use of bronchodilators or medical interventions
* usage of immunosuppressants before enrollment and the dose of immunosuppressant used ≥ 10mg / day oral prednisone for more than 2 weeks
* serious allergy
* serious mental diseases
* abnormal coagulation funtion,bleeding tendency or receiving thrombolytic or anticoagulant therapy
* abdominal fistula, gastrointestinal perforation, or abdominal abscess within 4 weeks prior to enrollment
* previous or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, severe lung damage, etc.
* other situations evaluated by investigator unsuitable for this study

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No